|
 |
Dr. Strijkert is a Director of Paratek Pharmaceuticals.
He was formerly on the Board of Management of Royal Gist-brocades
NV (Delft). He is a Director of Chiron Corporation and of deVGen
NV (Ghent, Belgium). He is Chairman of the Supervisory Board of
Introgene (Leiden), Pharming BV (Leiden), and UbiSys NV (Utrecht).
He is Chairman of the Board of the New Drug Research Foundation
(The Hague) and Chairman of the Committee “Biotechnology”
(Amsterdam). He has served as Chairman of the Board of International
Biosynthetics BV, as Chairman of the Board of External Management
Partners Holding BV (Staverden), and as a board member of the Association
of the Dutch Chemical Industry (VNCI), the Bureau EG-Liaison, the
Senior Advisory Group on Biotechnology (Brussels), and the Foundation
for the Preservation of the Central Laboratory of the Netherlands
Red Cross Blood Transfusion Service. He is also an advisory board
member for a number of other institutions, including Eidgenossische
Technische Hochschule Institut für Biotechnologie (Zurich).
|
